A perspective on the sickle cell disease international COVID-19 registry. Best Pract Res Clin Haematol 2022 Sep;35(3):101385
Date
12/10/2022Pubmed ID
36494148Pubmed Central ID
PMC9509018DOI
10.1016/j.beha.2022.101385Scopus ID
2-s2.0-85140073334 (requires institutional sign-in at Scopus site)Abstract
To understand the risks and outcomes of COVID-19 in the sickle cell disease (SCD) population, our team established a rapid reporting registry to collect data on the course of COVID-19 illness in individuals with SCD. The registry includes cases reported voluntarily by providers. All data are collected through an online case report form available at covidsicklecell.org. The registry helped to recognize patients with SCD as a population at risk of severe COVID-19 illness and to identify comorbidities that put them at higher risk. In this report, we present data on 1045 reported COVID-19 cases based during a two-year long data collection period. Data include 590 (56.5%) children and 455 (43.5%) adults; 51.2% of total population were female. Most individuals (63.1%) had HbSS genotype. Majority of individuals experienced mild symptoms (62.2% of children, 55.6% of adults). We also present a perspective on setting up the registry and experiences through its growth.
Author List
Mucalo L, Brandow AM, Singh AAuthors
Amanda Brandow DO Professor in the Pediatrics department at Medical College of WisconsinAshima Singh PhD Assistant Professor in the Pediatrics department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AdultAnemia, Sickle Cell
Child
Female
Humans
Male
